Due to the urgent demand for this device was during the COVID-19 pandemic in 2020, we invented the concept, created the prototypes and managed the manufacturing process within just 3.5 months.

Its 1 mL plastic syringe can be filled on-site with the required medication, making the device ideal for use in hospitals, clinical studies, and acute treatments. Compact and ready-to-use, Pulmospray™ leverages proprietary Rayleigh spray nozzle technology to produce a gentle, efficient aerosol cloud, delivering effective therapy without the need for propellants.